Lowest Price Guaranteed From USD 4,899
The peptide drug discovery market is estimated to be worth $560 million in 2020 and is expected to grow at compounded annual growth rate (CAGR) of 10.5% during the forecast period.Over the past few years, peptides (including oligopeptides, polypeptides and synthetic peptides) and macrocycle-based pharmacological interventions have gained a lot of attention from clinical researchers; drug development efforts focused on such molecules have significantly increased. This can be attributed to the benefits offered by the aforementioned drug classes, which include high target specificity, low toxicity and favorable safety profiles. In fact, more than 60 peptide-based therapies and macrocycle drug molecules have been approved till date, across the globe. In addition, more than 400 peptide based drugs are currently being evaluated in clinical trials, while over 500 molecules are still in the early stages of development.
It has been reported that the overall process of drug development, from peptide discovery of a molecule to its commercial launch, takes around 10-15 years and involves capital investments worth USD 4-10 billion. However, only a small proportion of the molecules, which are selected for further investigation during the initial stages of research, actually enter the market. Given the complexities associated with the peptide drug discovery process, the overall research and development (R&D) expenditure in the pharmaceutical / biotechnology sector has steadily increased over time. Specifically, the discovery of peptides and macrocycles for therapeutic use is a long, arduous and cost intensive process. As a result, many developers are opting to outsource such operations to contract research organizations (CROs) that claim to specialize in this regard. In addition, there are multiple technology platform providers, which offer licenses to proprietary peptide discovery platforms that can be used by interested drug developers / manufacturers. We believe that, as the demand for peptide-based therapeutics increases, the opportunity for contract service provides and technology developers engaged in peptide drug discovery market is also likely to witness a substantial market growth during the forecast period.
Examples of key companies engaged in peptide drug discovery market (which have also been profiled in this market report; the complete list of companies is available in the full report) include GenScript, JPT Peptide Technologies, CPC Scientific, IRBM, Creative Peptides, Pepscan, Interprotein, RA Pharmaceuticals, Pepticom, PeptiDream, Creative Biolabs and MeSCue-Janusys. This market report includes an easily searchable excel database of all the companies providing peptide drug discovery platforms and services, worldwide.
Several recent developments have taken place in the field of peptide drug discovery market. We have outlined some of these recent initiatives below. These developments, even if they took place post the release of our market report, substantiate the overall market trends that have been outlined in our analysis.
The “Peptide Drug Discovery Market, 2020-2030” market report features an extensive study on the current market landscape, market size, market share, market growth, market trends, market value, market forecast, market outlook, statistics and future opportunities of the peptide drug discovery market. The market research report includes in-depth analyses, highlighting the capabilities of various service / technology providers engaged in this market. Amongst other elements, the market research report includes:
The key objective of peptide drug discovery market report is to provide a detailed market analysis in order to estimate the existing market size, market share, market growth, market trends, market value, market forecast, market outlook, statistics and future opportunity for peptide drug discovery market during the forecast period. Based on multiple parameters, such as R&D spend, we have developed an informed estimate on the financial evolution of the market over the forecast period, 2020-2030. The market report also provides details on the likely distribution of the current and forecasted opportunity across [A] different type of product (synthetic peptides, biological and recombinant peptides and macrocycles), [B] drug discovery steps (target identification and validation, hit identification, lead generation and lead optimization), [C] therapeutic area (oncological disorders, metabolic disorders, cardiovascular disorders, infectious disorders, urological disorders, endocrine disorders, CNS disorders, and other diseases), [D] company size (small, mid-sized and large and very large companies) and [E] geography (North America, Europe, Asia Pacific). To account for the uncertainties associated with the drug discovery services and to add robustness to our model, we have provided three market forecast scenarios, portraying the conservative, base and optimistic tracks of the market’s evolution.
The opinions and insights presented in the market report were influenced by discussions held with senior stakeholders in the industry. The market research report features detailed transcripts of interview(s) held with the following industry stakeholders:
All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this market research report are in USD, unless otherwise specified.